ID
17761
Description
NCT00334568/ GSK-AVA100193: M.Alzheimer GSK A 24 week double-blind, randomized, placebo-controlled, parallel-group dose-raging study to investigate the effects of rosiglitazone (extended release tablets) on cognition in subjects with mild to moderate Alzheimer´s disease. Medicine: rosiglitazone, Condition: Alzheimer´s Disease, Phase: 2, Clinical Study ID: AVA 100193, Sponsor: GSK. This ODM contains the Early Withdrawal.
Keywords
Versions (2)
- 10/3/16 10/3/16 -
- 12/9/16 12/9/16 -
Uploaded on
October 3, 2016
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
NCT00334568/ GSK-AVA100193: M.Alzheimer GSK - Early Withdrawal
NCT00334568/ GSK-AVA100193: M.Alzheimer GSK - Early Withdrawal
- StudyEvent: ODM
Description
Instructions
Description
Vital signs
Description
Weight
Data type
float
Measurement units
- kg
Description
Blood pressure and heart rate will be measured once, after the subject sits quietly for at least 5 minutes.
Data type
integer
Description
Blood pressure
Data type
integer
Measurement units
- mmHg
Description
Heart rate
Data type
integer
Measurement units
- bpm
Description
Central Laboratory (Non Fasting Samples)
Description
Concomitant Medications
Description
Adverse Events
Description
Physical Examination
Description
Pedal Oedema
Description
Further Instructions
Similar models
NCT00334568/ GSK-AVA100193: M.Alzheimer GSK - Early Withdrawal
- StudyEvent: ODM